Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,614.00
(
-0.45%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
105.25
(
0.78%
)
Bitcoin
70,700.00
(
1.15%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 54
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: biophud post# 41558

Saturday, 02/03/2007 7:37:25 PM

Saturday, February 03, 2007 7:37:25 PM

Post# of 257262
One little known difference for atacicept is it deals with not only BLyS and APRIL, but also a heterotrimer that has been shown to induce B-cell proliferation in vitro. If that heterotrimer indeed has some causality in vivo, then only atacicept has the ability to get at it.

Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now